# Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain

> **NCT06747728** · NA · RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 20 (estimated)

## Conditions studied

- Brain Glioma

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06747728
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06747728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06747728, "Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06747728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*